Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page " b$ M7 w3 e) e% L. `$ @* f5 S
1 l2 b/ A M, j6 A0 }
! ~3 G1 ^3 V% ]1 ESub-category:" T/ Z. l3 P; R' }
Molecular Targets
; K1 K4 I9 b1 N: e" O
5 D0 m' A9 s8 j; _: u
3 S3 ]! j( l; {" n" j) O5 A5 q7 mCategory:
4 {# t- T% d0 ?& i+ @( ^) l2 vTumor Biology 5 z1 u) J1 ^5 V& H8 I# a' i& [
; d2 W. b8 f! r: z* \8 T
) h$ I5 n! d! L1 }' h
Meeting:! t4 ]5 ^8 d* W! j1 q- F# t
2011 ASCO Annual Meeting ) ]; T Z0 f4 l- Q7 g& N
, ]& D) K% ^# C% v# r: D6 E
& q. N/ J' ?; Y6 d# G7 QSession Type and Session Title:9 D, T8 { m: F: s
Poster Discussion Session, Tumor Biology $ j% I) [9 d/ t6 E& g0 U n
' d6 I5 Z( n6 W6 J) }7 O X, D2 _ p' g
Abstract No:
0 _" c, ]+ F$ Q3 L) x, E2 |10517
4 T; @' w# L8 J" j$ c. A$ M7 S$ u
, I7 _4 U6 [' ]! c2 v; ~+ [! A' m5 Z4 p* G h
Citation:& l8 O) A0 Z/ q, g: K- \/ q% T6 x
J Clin Oncol 29: 2011 (suppl; abstr 10517) % V4 `. M8 g, _
. d2 V5 d! s9 W( L0 _2 u R
1 a0 ]% a7 A1 c8 ]
Author(s):5 m: f! g6 s/ z/ g) ]
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
1 N7 w) A( L, c% y" Q* Y% l7 o
u7 K& a. P6 ?, q: d; }: U% G* _4 B- g# `! J
- d( K; O% Z3 M" B
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
( |* \% {% z$ ^' ^+ \+ F; U+ K% q) x5 R7 d1 m) a( H0 l
Abstract Disclosures
% G* k: |& u' g( D9 d5 i" F1 C$ F
Abstract:
! w: K5 \- @7 ?# a( t8 r7 i& s$ f2 S% X1 y
y! g' V1 z. O% D& r0 l/ RBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.7 r; I" M: Y. u7 o
" ?8 G1 Y3 T* Y+ d% H
& Y1 B; _+ K) i1 J7 n- B |
4 W. Z$ M+ h% i2 @2 M" y; L
显身卡
